Contributor: COVID-19 Ranked Among the Top 5 Telehealth Diagnoses Nationally in April 2022
July 6th 2022COVID-19 was ranked in the top 5 diagnoses through telehealth in the Midwest, Northeast, and West regions as well as nationally in the month of April, coinciding with an increase in COVID-19 cases.
Read More
How Machine Learning, Digital Therapeutics Improve Personalized Care
July 5th 2022Panelists at the National Alliance of Healthcare Purchaser Coalitions 2022 Leadership Summit discussed the latest innovations in digital therapeutics and how they benefit patients on an individual and broad scale.
Read More
Evaluating Value-Based Contracting in Behavioral Health: A Q&A With Vanessa Bobb, MD, PhD, FAPA
July 5th 2022At AHIP 2022, Vanessa Bobb, MD, PhD, FAPA, vice president of Behavioral Health & Medical Integration at CDPHP, moderated a session on real-world study findings showcasing cost and quality benefits of value-based contracting in behavioral health. Bobb discusses findings of the study and how value-based programs can be better leveraged in mental health and substance abuse care.
Read More
Hypomethylating Agents Can Produce Long Remission of MPNs but May Contribute to Morbidity, Mortality
July 4th 2022Hypomethylating agents are a widely used treatment option in acute myeloid leukemia secondary to myeloproliferative neoplasms (MPNs), but careful monitoring of thromboembolic risk is needed for optimal outcomes.
Read More
Assessing Longitudinal Trends in Essential Thrombocythemia, Polycythemia Vera Blood Counts
July 2nd 2022A recent study identified trends in blood counts, but did not find statistically significant associations between achieving hematological remission and clinical outcomes in polycythemia vera (PV) or essential thrombocythemia (ET).
Read More
Dupilumab Demonstrates Safety, Efficacy Across Several Type 2 Inflammatory Diseases
July 2nd 2022Research presented at the European Academy of Allergy and Clinical Immunology Annual Congress show the safety and efficacy of dupilumab across several progressive diseases with underlying type 2 inflammation, including eosinophilic esophagitis (EoE), severe asthma, and severe chronic rhinosinusitis with nasal polyps.
Read More
Initiation of Nusinersen for SMA Soon After Birth May Allow for Normal Outcomes
July 2nd 2022Publishing their findings on the earliest treated infants to date, the researchers detailed the outcomes of 2 patients treated with nusinersen in their first week of life after receiving a spinal muscular atrophy (SMA) prenatal diagnosis.
Read More
Dr Zahra Mahmoudjafari Explains How Payers Can Better Manage CAR T Costs, Increase Access
July 2nd 2022Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, explains some of the strategies that payers can use to improve cost management and increase patient access related to chimeric antigen receptor T-cell (CAR T) therapies.
Watch
Dr John Winkelman Discusses Which Populations Are Most At Risk for Restless Leg Syndrome
July 2nd 2022While prevalence of restless leg syndrome (RLS) increases with age, some kids may have it while presenting symptoms of growing pains, explained John Winkelman, MD, PhD, medical director, sleep disorders clinical research program, Massachusetts General Hospital.
Watch
Exercise Capacity in HFpEF Not Impaired by Reduced Diastolic Filling Time
July 2nd 2022Using chronotropic response as a reference, study authors from Japan investigated the potential influence of exercise-induced heart rate on cardiac output reserve and exercise capacity among a cohort of patients with heart failure with preserved ejection fraction (HFpEF).
Read More
Dr Elaine Siegfried on Preventive Strategies to Reduce Comorbidity Risk in Atopic Dermatitis
July 2nd 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, addresses the comorbidity profile associated with atopic dermatitis and the utility of disease-modifying drugs to reduce risk of comorbid conditions.
Watch
Real-World Outcomes Explored in Studies of Bevacizumab Biosimilar for Metastatic Colorectal Cancer
July 2nd 2022Abstracts presented at the 2022 American Society of Clinical Oncology Annual Meeting show bevacizumab-awwb to be safe and effective for patients with metastatic colorectal cancer (mCRC) with high overall survival rates.
Read More